Pre-eclampsia and Biochemical Markers (PET)
|ClinicalTrials.gov Identifier: NCT02665897|
Recruitment Status : Completed
First Posted : January 28, 2016
Last Update Posted : June 9, 2017
In view of both endothelial injury in pre-eclampsia, high blood pressure and kidney impairment characteristics, a recent study demonstrated that the serum levels of NGAL increased at the end of the second trimester in women who subsequently developed pre-eclampsia compared to the control group.
This correlates well with the endothelial damage that occurs during pre-eclampsia and thus NGAL can be considered as a promising marker in predicting both early and late onset pre-eclampsia. It may be required to combine one or more biomarker with NGAL to increase the precision, and sensitivity for detection of risk and reliability of using biomarkers for pre-eclampsia.
|Condition or disease|
|Detection of Preeclampsia Complications|
|Study Type :||Observational|
|Actual Enrollment :||90 participants|
|Official Title:||Correlation Between Complications of Pre-eclampsia and Detection of Novel Biochemical Markers|
|Actual Study Start Date :||January 2016|
|Actual Primary Completion Date :||December 2016|
|Actual Study Completion Date :||May 2017|
pregnant women with eclampsia will be diagnosed by the occurrence of seizures on top of preeclampsia.
pregnant women with severe preeclampsia will be diagnosed according to blood pressure ≥160/110 mmHg with proteinuria detection by boiling method +3,+4.
matched normotensive pregnant women.
- The level of circulating NGAL [ Time Frame: 24 hours ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02665897
|Assiut, Cairo, Egypt, 002|